Ability Biologics, a Montreal, Canada-based premier cell targeting company, closed a $12m financing round.
The round was led by founding investor Amplitude Ventures with participation from Fonds de solidarité FTQ, Charles River Laboratories, Alexandria Venture Investments and Page One Ventures.
The company intends to use the funds to continue to develop its solutions.
Launched by Amplitude Ventures, working with co-founders Giles Day, CEO, and Jean-Philippe Bürckert, Vice President of Technology, Ability will use its AbiLeap™ discovery engine to systematically generate logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics.
The AbiLeap™ discovery engine combines an Artificial Intelligence (AI) platform with a large database of antibody-antigen interactions, bringing together more than five years of discovery data, incorporating both public and private data sources. This allows the company to address a longstanding challenge by generating fully human antibodies that are logic-gated, enabling them to target specific tissues and cells based on the local microenvironment dictated by conditions such as pH, temperature, or the presence of certain metabolites.
Ability has already established a partnership with Charles River Laboratories, a global provider of drug discovery and non-clinical development solutions.
FinSMEs
06/12/2023